Dyne Therapeutics, Inc. (DYN) earnings date

Nasdaq · Mid cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 37 days, typically, give or take 12 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 5, 2026before open 36 8-K
Q2 FY2026Wed, Jul 29, 2026after close 29 8-K
Q1 FY2026Mon, May 11, 2026before open 41 8-K
Q4 FY2025Mon, Mar 2, 2026before open 61 8-K
Q3 FY2025Wed, Nov 5, 2025after close 36 8-K
Q2 FY2025Mon, Jul 28, 2025after close 28 8-K
Q1 FY2025Thu, May 8, 2025before open 38 8-K
Q4 FY2024Thu, Feb 27, 2025before open 58 8-K

What they guided beta

Q3 FY2026 "“This includes preparations for the potential U.S. launch of z-rostudirsen for exon 51 DMD, if approved, and topline data from the registrational expansion cohort of the ACHIEVE trial for z-basivarsen in DM1, both expected in the first quarter of 2027." exhibit
Q3 FY2026 "Dyne continues to expect a potential U.S. launch of z-rostudirsen in Q1 2027, assuming approval is received on the anticipated timeline." exhibit
Q3 FY2026 "Dyne expects a potential U.S. launch of z-basivarsen in H1 2028, assuming the FDA grants Priority Review and approval is received on the anticipated timeline." exhibit
Q3 FY2026 "The Company expects that its cash, cash equivalents and marketable securities as of September 30, 2026, will be sufficient to fund its operations into the second quarter of 2028." exhibit
Q2 FY2026 "Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Biologics License Application (BLA) for z-rostudirsen in exon 51 DMD accepted for review by FDA; Priority Review granted; PDUFA target action date set for January 21, 2027 - - Completed enrollment of 71 participants in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1; topline data planned for Q1 2027 - - Investigational New Drug (IND) Application cleared by FDA for DYNE-302 in FSHD - - Expected cash runway into Q2 2028 - WALTHAM, Mass., July 29, 2026 – Dyne Therape" exhibit
Q2 FY2026 "Dyne continues to expect a potential U.S. launch of z-rostudirsen in Q1 2027, assuming approval is received on the anticipated timeline." exhibit
Q2 FY2026 "Dyne expects a potential U.S. launch of z-basivarsen in H1 2028, assuming the FDA grants Priority Review and approval is received on the anticipated timeline." exhibit
Q2 FY2026 "The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2026, together with the net proceeds from the July 2026 underwritten public offering, will be sufficient to fund its operations into the second quarter of 2028." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/DYN
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/DYN

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

DYN earnings date badge

HTML

<a href="https://veritasdata.dev/company/DYN/"><img src="https://veritasdata.dev/embed/DYN.svg" alt="DYN earnings date" width="240" height="56"></a>

Markdown

[![DYN earnings date](https://veritasdata.dev/embed/DYN.svg)](https://veritasdata.dev/company/DYN/)

Script

<script async src="https://veritasdata.dev/embed/DYN.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/DYN"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.